Merck Sharp & Dohme (MRK) to Present New Data at the 49th European Association for the Study of Diabetes Annual Meeting
9/19/2013 11:24:34 AM
September 19, 2013 -- MSD, known as Merck (NYSE: MRK) in the United States and Canada, will present seven new studies, including a comparison study of DPP-4 inhibition between patients with type 2 diabetes treated with JANUVIA® (sitagliptin), saxagliptin and vildagliptin at the 49th European Association for the Study of Diabetes (EASD) Annual Meeting being held in Barcelona, Spain, September 23-27, 2013.
Sitagliptin is a selective, once-daily DPP-4 inhibitor that increases active GLP-1 and GIP hormones, part of the incretin system that helps regulate blood sugar1. Sitagliptin inhibits the DPP-4 enzyme over 24 hours1. Sitagliptin was the first approved compound in the DPP-4 inhibitor class of oral treatments. Sitagliptin has been approved in more than 107 countries, and to date, more than 58 million prescriptions have been dispensed for the sitagliptin family of products worldwide2.
Scientific Abstracts to be Presented SITAGLIPTIN
- Comparison of Trough Dipeptidyl Peptidase-4 Inhibition in Patients With Type 2 Diabetes Treated With Saxagliptin, Sitagliptin, and Vildagliptin (114--OP; Wednesday, September 25, 2013 4:15 – 4:30 PM)
- Effects of 6 Weeks Treatment With Sitagliptin on Counterregulatory and Incretin Hormones During Acute Hypoglycaemia in Patients With Type 1 Diabetes (599--P; Tuesday, September 24, 2013 1:45 – 2:45 PM)
BURDEN OF URINARY TRACT INFECTIONS
- Prevalence of Urinary Tract Infection Among Type 2 Diabetes Mellitus Patients vs Non-diabetic Patients in
Germany (1317--P; Tuesday, September 24, 2013 12:30 – 1:30 PM)
- Disease Burden of Urinary Tract Infections Among Type 2 Diabetes Mellitus Patients: a US Database
Study (1318--P; Tuesday, September 24, 2013 12:30 – 1:30 PM)
- Meta-Analysis of Studies Examining Medication Adherence to Oral Antihyperglycaemic Agents in Type 2
Diabetes (270--P; Tuesday, September 24, 2013 12:30 – 1:30 PM)
- Oxyntomodulin Has Significant Acute Glucoregulatory Effects Comparable to Liraglutide in Subjects With
Type 2 Diabetes (48--O; Tuesday, September 24, 2013 4:15 – 4:30 PM)
- A Long-Acting Oxyntomodulin Derivative Exerts Superior Body Weight Lowering to GLP1R Agonism in
Monkeys (641--P; Thursday, September 26, 2013 1:45 – 2:45 PM)
About JANUVIA® (sitagliptin)
For safety Information about sitagliptin and before initiating therapy, please consult the full prescribing
Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of
Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines,
vaccines, biologic therapies, and consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.msd.com or www.msd.xx (for country-specific website) and connect with us on
Twitter, Facebook and YouTube.
MSD Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of MSD’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s/Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
JANUVIA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
1. JANUVIA Worldwide Product Circular 2012
2. TRx Monthly May 2013
Help employers find you! Check out all the jobs and post your resume.
comments powered by